Fresenius has agreed a deal to expand its offering of homecare products via the acquisition of fellow medical company Gambro's worldwide peritoneal dialysis (PD) business.
The deal, which remains subject to regulatory approval, will see Fresenius add approximately $60 million (39 million pounds) to its annual revenue, as well as cater better to the 11 per cent of global dialysis patients treated by means of PD.
In addition, the transaction will enable Fresenius to expand its presence in the European and Asia-Pacific markets, territories in which Gambro has a focus.
Ben Lipps, chief executive officer of Fresenius Medical Care, expressed confidence that the purchase will support the company's overall growth strategy in the home therapy sector.
He added: "Bringing together the experienced PD teams of both companies and our mutual focus on biocompatible PD solutions for high-quality patient care will give us a unique opportunity to complete our PD product offering."
Last month, the company published its financial report for the first half of 2010, during which the firm saw an 11 per cent increase in sales year-on-year.See all the latest jobs in Medical Devices